Advertisement

Salvage brachytherapy for localized prostate cancer after radiotherapy failure1

      Abstract

      Objectives. To evaluate the effectiveness and morbidity of salvage brachytherapy for locally recurrent or persistent prostate cancer after radiotherapy failure.
      Methods. In this retrospective study, 49 patients of median age 73.3 years (range 52.9 to 86.9) with biopsy-proven localized prostate cancer underwent interactive transperineal fluoroscopic-guided and biplane ultrasound-guided brachytherapy with either iodine 125 or palladium 103 after prior radiotherapy failure. Post-treatment follow-up was conducted for a median of 64.1 months (range 26.6 to 96.8) and included clinical assessment of disease status, assays of serum prostate-specific antigen (PSA) levels, and documentation of treatment-related symptoms and complications. Determination of biochemical treatment failure was based on two successive rising PSA values above the post-treatment PSA nadir value.
      Results. The actuarial rate of local prostate cancer control was 98% (95% confidence interval [CI] 94% to 99%). Actuarial disease-specific survival at 3 and 5 years was 89% (95% CI 73% to 96%) and 79% (95% CI 58% to 91%), respectively. At 3 and 5 years, actuarial biochemical disease-free survival was 48% (95% CI 32% to 63%) and 34% (95% CI 17% to 51%), respectively. Post-treatment PSA nadir was found to be a significant predictor of biochemical disease-free survival. Actuarial biochemical disease-free survival of patients who achieved a PSA nadir less than 0.5 ng/mL was 77% (95% CI 53% to 90%) and 56% (95% CI 25% to 78%) at 3 and 5 years, respectively. Of 49 patients, 23 (47%) achieved a post-treatment PSA nadir less than 0.5 ng/mL. The incidence of serious complications after salvage brachytherapy, such as incontinence and rectal complications, was lower than that reported after other types of salvage procedures.
      Conclusions. Interactive transperineal fluoroscopic-guided and biplane ultrasound-guided brachytherapy is a novel, potentially curative salvage modality for patients in whom prior radiotherapy failed. In a population of patients with poor prognosis, this modality was associated with a high rate of local prostate cancer control and a 34% actuarial rate of biochemical disease-free survival at 5 years. The incidence of major complications after salvage brachytherapy appears to be lower than that after other potentially curative salvage procedures, such as radical prostatectomy and cryoablation. Salvage brachytherapy warrants further investigation.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kaplan I.D.
        • Cox R.S.
        • Bagshaw M.A.
        Prostate specific antigen after external beam radiotherapy for prostatic cancer.
        J Urol. 1993; 149: 519-522
        • Stamey T.A.
        • Kabalin J.N.
        • Ferrari M.
        Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients.
        J Urol. 1989; 141: 1084-1087
        • Lee W.R.
        • Hanlon A.L.
        • Hanks G.E.
        Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer. The relationship between nadir level and disease-free survival.
        J Urol. 1996; 156: 450-453
        • Hanks G.E.
        • Martz K.L.
        • Krall J.M.
        • et al.
        Analysis of independent variables affecting survival after recurrence of prostate cancer.
        Int J Radiat Oncol Biol Phys. 1989; 16: 1431-1435
        • Lai P.P.
        • Perez C.A.
        • Lockett M.A.
        Prognostic significance of pelvic recurrence and distant metastasis in prostate carcinoma following definitive radiotherapy.
        Int J Radiat Oncol Biol Phys. 1992; 24: 423-430
        • Holzman M.
        • Carlton C.
        • Scardino P.T.
        The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer.
        J Urol. 1991; 146: 1578-1582
        • Zietman A.L.
        • Shipley W.U.
        • Willett C.G.
        Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications.
        Cancer. 1993; 71: 959-969
        • Zincke H.
        Radical prostatectomy and exenterative procedures for local failure after radiotherapy with curative intent.
        J Urol. 1992; 147: 894-899
        • Rainwater L.M.
        • Zincke H.
        Radical prostatectomy after radiation therapy for cancer of the prostate.
        J Urol. 1988; 140: 1455-1459
        • Thompson I.M.
        • Rounder J.B.
        • Spence C.R.
        • et al.
        Salvage radical prostatectomy for adenocarcinoma of the prostate.
        Cancer. 1988; 61: 1464-1466
        • Neerhut G.J.
        • Wheeler T.
        • Cantini M.
        • et al.
        Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate.
        J Urol. 1988; 140: 544-549
        • Moul J.W.
        • Paulson D.F.
        The role of radical surgery in the management of radiation recurrent and large volume prostate cancer.
        Cancer. 1991; 68: 1265-1271
        • Link P.
        • Freiha F.S.
        Radical prostatectomy after definitive radiation therapy for prostate cancer.
        Urology. 1991; 37: 189-192
        • Ahlering T.E.
        • Lieskovsky G.
        • Skinner D.G.
        Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma.
        J Urol. 1992; 147: 900-902
        • Stein A.
        • Smith R.B.
        • deKernion J.B.
        Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of prostate.
        Urology. 1992; 40: 197-200
        • Pontes J.E.
        • Montie J.
        • Klein E.
        • et al.
        Salvage surgery for radiation failure in prostate cancer.
        Cancer. 1993; 71: 976-980
        • Rogers E.
        • Ohori M.
        • Kassabian V.S.
        • et al.
        Salvage radical prostatectomy.
        J Urol. 1995; 153: 104-110
        • Catalona W.J.
        Management of cancer of the prostate.
        N Engl J Med. 1994; 331: 996-1004
        • Cohen J.K.
        • Miller R.J.
        • Rooker G.M.
        • et al.
        Cryosurgical ablation of the prostate.
        Urology. 1996; 47: 395-400
        • Miller Jr, R.J.
        • Cohen J.K.
        • Shuman B.
        • et al.
        Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post radiation recurrence of adenocarcinoma.
        Cancer. 1996; 77: 1510-1514
        • Bales G.T.
        • Williams M.J.
        • Sinner M.
        • et al.
        Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy.
        Urology. 1995; 46: 676-680
        • Waxman S.
        • Stevens A.K.
        • Walsh R.A.
        • et al.
        Management of asymptomatic rising PSA after prostatectomy or radiation therapy.
        Oncology (Huntingt). 1997; 11: 457-465
        • Patel B.G.
        • Parsons C.L.
        • Bidair M.
        • et al.
        Cryoablation for carcinoma of the prostate.
        J Surg Oncol. 1996; 63: 256-264
        • Stokes S.H.
        • Real J.D.
        • Adams P.W.
        • et al.
        Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate.
        Int J Radiat Oncol Biol Phys. 1997; 37: 337-341
        • Goffinet D.R.
        • Martinez A.
        • Freiha F.
        • et al.
        125iodine prostate implants for recurrent carcinomas after external beam irradiation.
        Cancer. 1980; 45: 2717-2724
        • Cumes D.M.
        • Goffinet D.R.
        • Martinez A.
        • et al.
        Complications of 125iodine implantation and pelvic lymphadenectomy for prostatic cancer with special references to patients who have failed external beam therapy as their initial mode of therapy.
        J Urol. 1981; 126: 620-622
        • Butler E.B.
        • Scardino P.T.
        • Teh B.S.
        • et al.
        The Baylor College of Medicine experience with gold seed implantation.
        Semin Surg Oncol. 1997; 13: 406-418
        • Dattoli M.
        • Cash J.
        • Ross R.
        • et al.
        Neoadjuvant hormone therapy and palladium-103 brachytherapy as salvage for locally recurrent prostate cancer.
        Proc Am Soc Clin Oncol. 1997; 16: 314a
        • Grado G.L.
        • Larson T.R.
        • Balch C.S.
        • et al.
        Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance.
        Int J Radiat Oncol Biol Phys. 1998; 42: 289-298
        • Utz D.C.
        • Farrow G.M.
        Pathologic differentiation and prognosis of prostatic carcinoma.
        JAMA. 1969; 209: 1701-1703
        • Gleason D.F.
        Histologic grading and clinical staging of prostatic carcinoma.
        in: Tannenbaum M. Urologic Pathology The Prostate. Lea & Febinger, Philadelphia1977: 171-198
        • Holm H.H.
        • Juul N.
        • Pedersen J.F.
        • et al.
        Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography.
        J Urol. 1983; 130: 283-286
        • Nag S.
        Transperineal iodine-125 implantation of the prostate under transrectal ultrasound and fluoroscopic control.
        Endocurie/Hypertherm Oncol. 1985; 1: 207-211
        • Ragde H.
        • Blasko J.C.
        • Schumacher D.
        Use of transrectal ultrasound in transperineal iodine-125 seeding for prostate cancer.
        J Endourol. 1989; 3: 209-218
        • Nath R.
        • Anderson L.L.
        • Luxton G.
        • et al.
        Dosimetry of interstitial brachytherapy sources.
        Med Phys. 1995; 22: 209-234
        • Luse R.W.
        • Blasko J.
        • Grimm P.
        A method for implementing the American Association of Physicists in Medicine Task Group-43 dosimetry recommendations for 125I transperineal prostate seed implants on commercial treatment planning systems.
        Int J Radiat Oncol Biol Phys. 1997; 37: 737-741
        • Wheeler J.A.
        • Zagars G.K.
        • Ayala A.G.
        Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression.
        Cancer. 1993; 71: 3783-3787
        • Schellhammer P.F.
        • el-Mahdi A.M.
        • Wright G.L.
        • et al.
        Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate.
        Urology. 1993; 42: 13-20
        • Critz F.A.
        • Tarlton R.S.
        • Holladay D.A.
        Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation.
        Cancer. 1995; 75: 2383-2391
        • Schellhammer P.F.
        • Kuban D.A.
        • el-Mahdi A.M.
        Local failure after definitive radiation or surgical therapy for carcinoma of the prostate and options for prevention and therapy.
        Urol Clin North Am. 1991; 18: 485-499
        • Kuban D.A.
        • el-Mahdi A.M.
        • Schellhammer P.F.
        Prognosis in patients with local recurrence after definitive irradiation for prostatic carcinoma.
        Cancer. 1989; 63: 2421-2425
        • Dattoli M.
        • Wallner K.
        • Sorace R.
        • et al.
        103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma.
        Int J Radiat Oncol Biol Phys. 1996; 35: 875-879
        • D’Amico A.V.
        • Coleman C.N.
        Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer.
        J Clin Oncol. 1996; 14: 304-315
        • Beyer D.C.
        • Priestley J.B.
        Biochemical disease-free survival following 125I prostate implantation.
        Int J Radiat Oncol Biol Phys. 1997; 37: 559-563
        • Blasko J.G.
        • Grimm P.D.
        • Padge H.
        External beam irradiation with palladium-103 implantation for prostate carcinoma.
        Int J Radiat Oncol Biol Phys. 1994; 30: 219
        • Blasko J.C.
        • Wallner K.
        • Grimm P.D.
        • et al.
        Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma.
        J Urol. 1995; 154: 1096-1099
        • Kaye K.W.
        • Olson D.J.
        • Payne J.T.
        Detailed preliminary analysis of 125iodine implantation for localized prostate cancer using percutaneous approach.
        J Urol. 1995; 153: 1020-1025
        • Ragde H.
        • Blasko J.C.
        • Grimm P.D.
        • et al.
        Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma.
        Cancer. 1997; 80: 442-453
        • Wallner K.
        • Roy J.
        • Harrison L.
        Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma.
        J Clin Oncol. 1996; 14: 449-453
        • Arterbery V.E.
        • Frazier A.
        • Dalmia P.
        • et al.
        Quality of life after permanent prostate implant.
        Semin Surg Oncol. 1997; 13: 461-464
        • Cespedes R.D.
        • Pisters L.L.
        • von Eschenbach A.C.
        • et al.
        Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of the prostate.
        J Urol. 1997; 157: 237-240
        • Lerner S.E.
        • Blute M.L.
        • Zincke H.
        Critical evaluation of salvage surgery for radiorecurrent/resistant prostate cancer.
        J Urol. 1995; 154: 1103-1109